FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy.


Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
10 Apr 2024
Historique:
received: 13 02 2023
accepted: 27 02 2024
medline: 11 4 2024
pubmed: 11 4 2024
entrez: 10 4 2024
Statut: aheadofprint

Résumé

Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment of haematological malignancies such as acute lymphoblastic leukaemia, B cell lymphoma and multiple myeloma

Identifiants

pubmed: 38600376
doi: 10.1038/s41586-024-07242-1
pii: 10.1038/s41586-024-07242-1
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s).

Références

Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014).
pubmed: 25317870 pmcid: 4267531 doi: 10.1056/NEJMoa1407222
Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73 (2011).
pubmed: 21832238 pmcid: 3393096 doi: 10.1126/scitranslmed.3002842
Rodriguez-Otero, P. et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N. Engl. J. Med. 388, 1002–1014 (2023).
pubmed: 36762851 doi: 10.1056/NEJMoa2213614
San-Miguel, J. et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N. Engl. J. Med. 389, 335–347 (2023).
pubmed: 37272512 doi: 10.1056/NEJMoa2303379
Mardiana, S., Solomon, B. J., Darcy, P. K. & Beavis, P. A. Supercharging adoptive T cell therapy to overcome solid tumor-induced immunosuppression. Sci. Transl. Med. 11, eaaw2293 (2019).
pubmed: 31167925 doi: 10.1126/scitranslmed.aaw2293
Chan, J. D. et al. Cellular networks controlling T cell persistence in adoptive cell therapy. Nat. Rev. Immunol. 21, 769–784 (2021).
pubmed: 33879873 doi: 10.1038/s41577-021-00539-6
van Bruggen, J. A. C. et al. Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8
pubmed: 31076448 pmcid: 7022375 doi: 10.1182/blood.2018885863
Fraietta, J. A. et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24, 563–571 (2018).
pubmed: 29713085 pmcid: 6117613 doi: 10.1038/s41591-018-0010-1
Blank, C. U. et al. Defining T cell exhaustion. Nat. Rev. Immunol. 19, 665–674 (2019).
pubmed: 31570879 pmcid: 7286441 doi: 10.1038/s41577-019-0221-9
Giraldo, N. A. et al. Tumor-infiltrating and peripheral blood T-cell immunophenotypes predict early relapse in localized clear cell renal cell carcinoma. Clin. Cancer Res. 23, 4416–4428 (2017).
pubmed: 28213366 doi: 10.1158/1078-0432.CCR-16-2848
Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998–1013.e20 (2019).
doi: 10.1016/j.cell.2018.10.038
Giuffrida, L. et al. IL-15 preconditioning augments CAR T cell responses to checkpoint blockade for improved treatment of solid tumors. Mol. Ther. 28, 2379–2393 (2020).
pubmed: 32735774 pmcid: 7647667 doi: 10.1016/j.ymthe.2020.07.018
Klebanoff, C. A. et al. Central memory self/tumor-reactive CD8
pubmed: 15980149 pmcid: 1172264 doi: 10.1073/pnas.0503726102
Siddiqui, I. et al. Intratumoral Tcf1
pubmed: 30635237 doi: 10.1016/j.immuni.2018.12.021
Guo, Y. et al. Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers. Clin. Cancer Res. 24, 1277–1286 (2018).
pubmed: 29138340 doi: 10.1158/1078-0432.CCR-17-0432
Soriano-Baguet, L. & Brenner, D. Metabolism and epigenetics at the heart of T cell function. Trends Immunol. 44, 231–244 (2023).
pubmed: 36774330 doi: 10.1016/j.it.2023.01.002
Weber, E. W. et al. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science 372, eaba1786 (2021).
pubmed: 33795428 pmcid: 8049103 doi: 10.1126/science.aba1786
Hirabayashi, K. et al. Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors. Nat. Cancer 2, 904–918 (2021).
pubmed: 34746799 pmcid: 8570569 doi: 10.1038/s43018-021-00244-2
Hurton, L. V. et al. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc. Natl Acad. Sci. USA 113, E7788–E7797 (2016).
pubmed: 27849617 pmcid: 5137758 doi: 10.1073/pnas.1610544113
Kagoya, Y. et al. BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models. J. Clin. Invest. 126, 3479–3494 (2016).
pubmed: 27548527 pmcid: 5004946 doi: 10.1172/JCI86437
Seo, H. et al. BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells. Nat. Immunol. 22, 983–995 (2021).
pubmed: 34282330 pmcid: 8319109 doi: 10.1038/s41590-021-00964-8
Lynn, R. C. et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 576, 293–300 (2019).
pubmed: 31802004 pmcid: 6944329 doi: 10.1038/s41586-019-1805-z
Alizadeh, D. et al. IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype. Cancer Immunol. Res. 7, 759–772 (2019).
pubmed: 30890531 pmcid: 6687561 doi: 10.1158/2326-6066.CIR-18-0466
Tejera, M. M., Kim, E. H., Sullivan, J. A., Plisch, E. H. & Suresh, M. FoxO1 controls effector-to-memory transition and maintenance of functional CD8 T cell memory. J. Immunol. 191, 187–199 (2013).
pubmed: 23733882 doi: 10.4049/jimmunol.1300331
Kerdiles, Y. M. et al. Foxo1 links homing and survival of naive T cells by regulating L-selectin, CCR7 and interleukin 7 receptor. Nat. Immunol. 10, 176–184 (2009).
pubmed: 19136962 pmcid: 2856471 doi: 10.1038/ni.1689
Chen, Z. et al. In vivo CD8
pubmed: 33636129 pmcid: 8054351 doi: 10.1016/j.cell.2021.02.019
Yang, C. Y. et al. The transcriptional regulators Id2 and Id3 control the formation of distinct memory CD8
pubmed: 22057289 doi: 10.1038/ni.2158
Utzschneider, D. T. et al. Active maintenance of T cell memory in acute and chronic viral infection depends on continuous expression of FOXO1. Cell Rep. 22, 3454–3467 (2018).
pubmed: 29590615 pmcid: 5942184 doi: 10.1016/j.celrep.2018.03.020
Klotz, L. O. et al. Redox regulation of FoxO transcription factors. Redox Biol. 6, 51–72 (2015).
pubmed: 26184557 pmcid: 4511623 doi: 10.1016/j.redox.2015.06.019
Beavis, P. A. et al. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. J. Clin. Invest. 127, 929–941 (2017).
pubmed: 28165340 pmcid: 5330718 doi: 10.1172/JCI89455
Dong, E. et al. IFN-γ surmounts PD-L1/PD1 inhibition to CAR-T cell therapy by upregulating ICAM-1 on tumor cells. Signal Transduct. Target. Ther. 6, 20 (2021).
pubmed: 33454722 pmcid: 7811529 doi: 10.1038/s41392-020-00357-7
Chmielewski, M., Kopecky, C., Hombach, A. A. & Abken, H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 71, 5697–5706 (2011).
pubmed: 21742772 doi: 10.1158/0008-5472.CAN-11-0103
Larson, R. C. et al. CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours. Nature 604, 563–570 (2022).
pubmed: 35418687 doi: 10.1038/s41586-022-04585-5
Mardiana, S. et al. A multifunctional role for adjuvant anti-4-1BB therapy in augmenting antitumor response by chimeric antigen receptor T cells. Cancer Res. 77, 1296–1309 (2017).
pubmed: 28082401 doi: 10.1158/0008-5472.CAN-16-1831
Kantari-Mimoun, C. et al. CAR T-cell entry into tumor islets is a two-step process dependent on IFNγ and ICAM-1. Cancer Immunol. Res. 9, 1425–1438 (2021).
pubmed: 34686489 doi: 10.1158/2326-6066.CIR-20-0837
Monteiro, L. B., Davanzo, G. G., de Aguiar, C. F. & Moraes-Vieira, P. M. M. Using flow cytometry for mitochondrial assays. MethodsX 7, 100938 (2020).
pubmed: 32551241 pmcid: 7289760 doi: 10.1016/j.mex.2020.100938
Jang, K. J. et al. Mitochondrial function provides instructive signals for activation-induced B-cell fates. Nat. Commun. 6, 6750 (2015).
pubmed: 25857523 doi: 10.1038/ncomms7750
Rad, S. M. A., Poudel, A., Tan, G. M. Y. & McLellan, A. D. Promoter choice: Who should drive the CAR in T cells? PLoS ONE 15, e0232915 (2020).
doi: 10.1371/journal.pone.0232915
Wherry, E. J. et al. Molecular signature of CD8
pubmed: 17950003 doi: 10.1016/j.immuni.2007.09.006
Shan, Q. et al. Tcf1–CTCF cooperativity shapes genomic architecture to promote CD8
pubmed: 35882936 pmcid: 9579964 doi: 10.1038/s41590-022-01263-6
Delpoux, A. et al. FOXO1 constrains activation and regulates senescence in CD8 T cells. Cell Rep. 34, 108674 (2021).
pubmed: 33503413 doi: 10.1016/j.celrep.2020.108674
Melenhorst, J. J. et al. Decade-long leukaemia remissions with persistence of CD4
pubmed: 35110735 pmcid: 9166916 doi: 10.1038/s41586-021-04390-6
Klebanoff, C. A. et al. Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy. JCI Insight 2, e95103 (2017).
pubmed: 29212954 pmcid: 5752304 doi: 10.1172/jci.insight.95103
Kousteni, S. FoxO1, the transcriptional chief of staff of energy metabolism. Bone 50, 437–443 (2012).
pubmed: 21816244 doi: 10.1016/j.bone.2011.06.034
Huang, Q. et al. The primordial differentiation of tumor-specific memory CD8
pubmed: 36208623 doi: 10.1016/j.cell.2022.09.020
Reinhard, K. et al. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science 367, 446–453 (2020).
pubmed: 31896660 doi: 10.1126/science.aay5967
Piechocki, M. P., Ho, Y. S., Pilon, S. & Wei, W. Z. Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines. J. Immunol. 171, 5787–5794 (2003).
pubmed: 14634087 doi: 10.4049/jimmunol.171.11.5787
Darcy, P. K. et al. Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL. J. Immunol. 164, 3705–3712 (2000).
pubmed: 10725729 doi: 10.4049/jimmunol.164.7.3705
DeLuca, D. S. et al. RNA-SeQC: RNA-seq metrics for quality control and process optimization. Bioinformatics 28, 1530–1532 (2012).
pubmed: 22539670 pmcid: 3356847 doi: 10.1093/bioinformatics/bts196
Zerbino, D. R. et al. Ensembl 2018. Nucleic Acids Res. 46, D754–D761 (2018).
pubmed: 29155950 doi: 10.1093/nar/gkx1098
Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2010).
pubmed: 19910308 doi: 10.1093/bioinformatics/btp616
McCarthy, D. J., Chen, Y. & Smyth, G. K. Differential expression analysis of multifactor RNA-seq experiments with respect to biological variation. Nucleic Acids Res. 40, 4288–4297 (2012).
pubmed: 22287627 pmcid: 3378882 doi: 10.1093/nar/gks042
Korotkevich, G., Sukhov, V. & Sergushichev, A. Fast gene set enrichment analysis. Preprint at bioRxiv https://doi.org/10.1101/060012 (2019).
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
pubmed: 16199517 pmcid: 1239896 doi: 10.1073/pnas.0506580102
Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739–1740 (2011).
pubmed: 21546393 pmcid: 3106198 doi: 10.1093/bioinformatics/btr260
Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417–425 (2015).
pubmed: 26771021 pmcid: 4707969 doi: 10.1016/j.cels.2015.12.004
Kanehisa, M. & Goto, S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 28, 27–30 (2000).
pubmed: 10592173 pmcid: 102409 doi: 10.1093/nar/28.1.27
Pont, F., Tosolini, M. & Fournie, J. J. Single-cell signature explorer for comprehensive visualization of single cell signatures across scRNA-seq datasets. Nucleic Acids Res. 47, e133 (2019).
pubmed: 31294801 pmcid: 6868346 doi: 10.1093/nar/gkz601
Gaspar, J. M. NGmerge: merging paired-end reads via novel empirically-derived models of sequencing errors. BMC Bioinformatics 19, 536 (2018).
pubmed: 30572828 pmcid: 6302405 doi: 10.1186/s12859-018-2579-2
Pohl, A. & Beato, M. bwtool: a tool for bigWig files. Bioinformatics 30, 1618–1619 (2014).
pubmed: 24489365 pmcid: 4029031 doi: 10.1093/bioinformatics/btu056
Schep, A. N., Wu, B., Buenrostro, J. D. & Greenleaf, W. J. chromVAR: inferring transcription-factor-associated accessibility from single-cell epigenomic data. Nat. Methods 14, 975–978 (2017).
pubmed: 28825706 pmcid: 5623146 doi: 10.1038/nmeth.4401
Castro-Mondragon, J. A. et al. JASPAR 2022: the 9th release of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 50, D165–D173 (2022).
pubmed: 34850907 doi: 10.1093/nar/gkab1113

Auteurs

Jack D Chan (JD)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

Christina M Scheffler (CM)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

Isabelle Munoz (I)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

Kevin Sek (K)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

Joel N Lee (JN)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

Yu-Kuan Huang (YK)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

Kah Min Yap (KM)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

Nicole Y L Saw (NYL)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

Jasmine Li (J)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

Amanda X Y Chen (AXY)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

Cheok Weng Chan (CW)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

Emily B Derrick (EB)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

Kirsten L Todd (KL)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

Junming Tong (J)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

Phoebe A Dunbar (PA)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

Jiawen Li (J)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

Thang X Hoang (TX)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

Maria N de Menezes (MN)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

Emma V Petley (EV)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

Joelle S Kim (JS)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

Dat Nguyen (D)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

Patrick S K Leung (PSK)

School of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria, Australia.

Joan So (J)

Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

Christian Deguit (C)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

Joe Zhu (J)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

Imran G House (IG)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

Lev M Kats (LM)

Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

Andrew M Scott (AM)

Olivia Newton-John Cancer Research Institute and School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia.
Faculty of Medicine, The University of Melbourne, Parkville, Victoria, Australia.

Benjamin J Solomon (BJ)

Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

Simon J Harrison (SJ)

Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
Clinical Haematology and Centre of Excellence for Cellular Immunotherapies, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia.

Jane Oliaro (J)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

Ian A Parish (IA)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

Kylie M Quinn (KM)

School of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria, Australia.
Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia.

Paul J Neeson (PJ)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

Clare Y Slaney (CY)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

Junyun Lai (J)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. junyun.lai@unimelb.edu.au.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia. junyun.lai@unimelb.edu.au.

Paul A Beavis (PA)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. paul.beavis@petermac.org.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia. paul.beavis@petermac.org.

Phillip K Darcy (PK)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. phil.darcy@petermac.org.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia. phil.darcy@petermac.org.
Clinical Haematology and Centre of Excellence for Cellular Immunotherapies, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia. phil.darcy@petermac.org.
Department of Immunology, Monash University, Clayton, Victoria, Australia. phil.darcy@petermac.org.

Classifications MeSH